Received Dec 17, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEP | HEP B (ENGERIX-B) | GLAXOSMITHKLINE BIOLOGICALS | UNK | 42D7A | — |
Engerix B pediatric dose given to adult patient; Engerix B pediatric dose given to adult patient; This non-serious case was reported by a other health professional via call center representative and described the occurrence of adult use of a child product in a 66-year-old female patient who received HBV (Engerix B pediatric) (batch number 42D7A, expiry date 25-JUL-2026) for prophylaxis. On 09-DEC-2025, the patient received Engerix B pediatric. On 09-DEC-2025, an unknown time after receiving Engerix B pediatric, the patient experienced adult use of a child product (Verbatim: Engerix B pediatric dose given to adult patient) and underdose (Verbatim: Engerix B pediatric dose given to adult patient). The outcome of the adult use of a child product and underdose were not applicable. Additional Information: GSK Receipt Date: 11-DEC-2025 The Vaccine Administration Facility was the same as Primary Reporter A clinic supervisor reported that a pediatric dose of Engerix B was given to an adult patient. Supervisor mentioned patient that received the vaccine was an employee at their facility.